|
C12ORF66 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.31500005223972E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.35439999993103E-07 |
| Normal-vs-Stage2 |
5.180100E-03 |
| Normal-vs-Stage3 |
2.35510000390349E-08 |
| Normal-vs-Stage4 |
6.83469999485098E-08 |
| Stage1-vs-Stage2 |
3.490200E-01 |
| Stage1-vs-Stage3 |
7.439700E-02 |
| Stage1-vs-Stage4 |
9.670300E-02 |
| Stage2-vs-Stage3 |
8.690200E-02 |
| Stage2-vs-Stage4 |
8.677900E-02 |
| Stage3-vs-Stage4 |
9.118400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.92550000388536E-08 |
| Normal-vs-AfricanAmerican |
8.358000E-04 |
| Normal-vs-Asian |
3.0075000045926E-08 |
| Caucasian-vs-AfricanAmerican |
9.974000E-01 |
| Caucasian-vs-Asian |
8.654000E-02 |
| AfricanAmerican-vs-Asian |
2.817200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.52440002235232E-09 |
| Normal-vs-Female |
6.38210000403205E-08 |
| Male-vs-Female |
7.549900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.08819999864596E-08 |
| Normal-vs-Age(41-60Yrs) |
3.27540000011339E-07 |
| Normal-vs-Age(61-80Yrs) |
9.70150000001446E-07 |
| Normal-vs-Age(81-100Yrs) |
3.942100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.453000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.516000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.104400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.080000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.718400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.956200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.780060E-02 |
| Classical-VS-Follicular |
8.673400E-01 |
| Classical-VS-Other |
2.089400E-01 |
| Classical-VS-Normal |
3.56749999541606E-08 |
| Tall-VS-Follicular |
1.081820E-01 |
| Tall-VS-Other |
6.420600E-01 |
| Tall-VS-Normal |
4.47110000134643E-08 |
| Follicular-VS-Other |
3.727600E-01 |
| Follicular-VS-Normal |
1.196440E-04 |
| Other-VS-Normal |
3.999200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.66729999993154E-08 |
| Normal-vs-N1 |
1.58550000017854E-07 |
| N0-vs-N1 |
1.663040E-01 |
|
|
